Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Novel targets for the treatment of relapsing multiple myeloma.

Giuliani N, Accardi F, Marchica V, Dalla Palma B, Storti P, Toscani D, Vicario E, Malavasi F.

Expert Rev Hematol. 2019 Jul;12(7):481-496. doi: 10.1080/17474086.2019.1624158. Epub 2019 Jun 3.

PMID:
31125526
2.

The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged.

Storti P, Agnelli L, Palma BD, Todoerti K, Marchica V, Accardi F, Sammarelli G, Deluca F, Toscani D, Costa F, Vicario E, Todaro G, Martella E, Neri A, Giuliani N.

Haematologica. 2019 Oct;104(10):e465-e469. doi: 10.3324/haematol.2018.209999. Epub 2019 Mar 7. No abstract available.

3.

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.

Marchica V, Toscani D, Corcione A, Bolzoni M, Storti P, Vescovini R, Ferretti E, Dalla Palma B, Vicario E, Accardi F, Mancini C, Martella E, Ribatti D, Vacca A, Pistoia V, Giuliani N.

Cancers (Basel). 2019 Mar 6;11(3). pii: E321. doi: 10.3390/cancers11030321.

4.

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts.

Muller J, Duray E, Lejeune M, Dubois S, Plougonven E, Léonard A, Storti P, Giuliani N, Cohen-Solal M, Hempel U, Thijssen VL, Beguin Y, Heusschen R, Caers J.

Cancers (Basel). 2019 Feb 23;11(2). pii: E261. doi: 10.3390/cancers11020261.

5.

Neurofibromatosis type I and multiple myeloma coexistence: A possible link?

Accardi F, Marchica V, Mancini C, Maredi E, Racano C, Notarfranchi L, Martorana D, Storti P, Martella E, Palma BD, Craviotto L, Filippo M, Percesepe A, Aversa F, Giuliani N.

Hematol Rep. 2018 Apr 3;10(1):7457. doi: 10.4081/hr.2018.7457. eCollection 2018 Mar 2.

6.

Possible targets to treat myeloma-related osteoclastogenesis.

Bolzoni M, Toscani D, Storti P, Marchica V, Costa F, Giuliani N.

Expert Rev Hematol. 2018 Apr;11(4):325-336. doi: 10.1080/17474086.2018.1447921. Epub 2018 Mar 9. Review.

PMID:
29495905
7.

Role of Galectins in Multiple Myeloma.

Storti P, Marchica V, Giuliani N.

Int J Mol Sci. 2017 Dec 17;18(12). pii: E2740. doi: 10.3390/ijms18122740. Review.

8.

Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.

Dalla Palma B, Marchica V, Pedrazzoni M, Accardi F, Notarfranchi L, Goldoni M, De Luca F, Costa F, Storti P, Toscani D, Sammarelli G, Bonomini S, Aversa F, Giuliani N.

Br J Haematol. 2018 Dec;183(5):812-815. doi: 10.1111/bjh.15026. Epub 2017 Nov 16. No abstract available.

PMID:
29143308
9.

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.

Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D, Accardi F, Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N.

Oncotarget. 2017 May 23;8(32):53053-53067. doi: 10.18632/oncotarget.18085. eCollection 2017 Aug 8.

10.

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S.

Cancer Cell. 2017 Jul 10;32(1):88-100.e6. doi: 10.1016/j.ccell.2017.05.011. Epub 2017 Jun 29.

11.

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, Todoerti K, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, Giuliani N.

Haematologica. 2017 Apr;102(4):773-784. doi: 10.3324/haematol.2016.153841. Epub 2017 Jan 5.

12.

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Marchica V, Accardi F, Storti P, Mancini C, Martella E, Dalla Palma B, Bolzoni M, Todoerti K, Marcatti M, Schifano C, Bonomini S, Sammarelli G, Neri A, Ponzoni M, Aversa F, Giuliani N.

Int J Hematol. 2017 Jan;105(1):104-108. doi: 10.1007/s12185-016-2104-1. Epub 2016 Oct 3.

PMID:
27699576
13.

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Storti P, Marchica V, Airoldi I, Donofrio G, Fiorini E, Ferri V, Guasco D, Todoerti K, Silbermann R, Anderson JL, Zhao W, Agnelli L, Bolzoni M, Martella E, Mancini C, Campanini N, Noonan DM, Petronini PG, Neri A, Aversa F, Roodman GD, Giuliani N.

Leukemia. 2016 Dec;30(12):2351-2363. doi: 10.1038/leu.2016.137. Epub 2016 May 20.

PMID:
27311934
14.

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, Todoerti K, Agnelli L, Missale G, Andreoli R, Bianchi MG, Allegri M, Barilli A, Nicolini F, Cavalli A, Costa F, Marchica V, Toscani D, Mancini C, Martella E, Dall'Asta V, Donofrio G, Aversa F, Bussolati O, Giuliani N.

Blood. 2016 Aug 4;128(5):667-79. doi: 10.1182/blood-2016-01-690743. Epub 2016 Jun 6.

15.

[The early management of the sepsis: use of a guidelines document in hospital. Experience at "Carlo Poma" Hospital in Mantova].

Gattuso G, Benazzi D, Ceruti R, Chiarelli C, Nespeca M, Dall'Oglio D, Lonati G, Marchioni M, Sgarioto V, Storti P, Tomasoni D, Castelli G, Costa P.

Recenti Prog Med. 2015 Nov;106(11):570-5. doi: 10.1701/2074.22496. Italian.

PMID:
26668043
16.

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Storti P, Toscani D, Airoldi I, Marchica V, Maiga S, Bolzoni M, Fiorini E, Campanini N, Martella E, Mancini C, Guasco D, Ferri V, Donofrio G, Aversa F, Amiot M, Giuliani N.

Haematologica. 2016 Mar;101(3):e107-10. doi: 10.3324/haematol.2015.133736. Epub 2015 Dec 11. No abstract available.

17.

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.

Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA.

Cancer Cell. 2015 May 11;27(5):644-57. doi: 10.1016/j.ccell.2015.04.007.

18.

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma.

Silbermann R, Bolzoni M, Storti P, Guasco D, Bonomini S, Zhou D, Wu J, Anderson JL, Windle JJ, Aversa F, Roodman GD, Giuliani N.

Leukemia. 2014 Apr;28(4):951-4. doi: 10.1038/leu.2013.385. Epub 2013 Dec 26. No abstract available.

19.

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maïga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot M, Aversa F, Roodman GD, Giuliani N.

Leukemia. 2013 Aug;27(8):1697-706. doi: 10.1038/leu.2013.24. Epub 2013 Jan 24.

PMID:
23344526
20.

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.

Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N.

Exp Hematol. 2013 Apr;41(4):387-97.e1. doi: 10.1016/j.exphem.2012.11.005. Epub 2012 Nov 23.

PMID:
23178378
21.

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M, Bonomini S, Agnelli L, Capocefalo A, Dalla Palma B, Neri A, Nicolini F, Lisignoli G, Russo F, Colla S, Aversa F, Giuliani N.

Leukemia. 2013 Feb;27(2):451-63. doi: 10.1038/leu.2012.190. Epub 2012 Jul 11.

PMID:
22781592
22.

Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.

Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla Palma B, Bonomini S, Martella E, Agnelli L, Neri A, Ceccarelli F, Palumbo C.

Leukemia. 2012 Jun;26(6):1391-401. doi: 10.1038/leu.2011.381. Epub 2012 Jan 6.

PMID:
22289923
23.

Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.

Agnelli L, Storti P, Todoerti K, Sammarelli G, Dalla Palma B, Bolzoni M, Rocci A, Piazza F, Semenzato G, Palumbo A, Neri A, Giuliani N.

Am J Hematol. 2011 Dec;86(12):E64-6. doi: 10.1002/ajh.22164. Epub 2011 Sep 22.

24.

Angiogenesis and multiple myeloma.

Giuliani N, Storti P, Bolzoni M, Palma BD, Bonomini S.

Cancer Microenviron. 2011 Dec;4(3):325-37. doi: 10.1007/s12307-011-0072-9. Epub 2011 Jul 7.

25.

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L, Abeltino M, Todoerti K, Lazzaretti M, Mancini C, Ribatti D, Bonomini S, Franceschi V, Pistoia V, Lisignoli G, Pedrazzini A, Cavicchi O, Neri A, Rizzoli V, Giuliani N.

Leukemia. 2011 Mar;25(3):527-37. doi: 10.1038/leu.2010.270. Epub 2010 Nov 23.

26.

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli V, Giuliani N.

Exp Hematol. 2011 Jan;39(1):55-65. doi: 10.1016/j.exphem.2010.10.005. Epub 2010 Oct 25.

PMID:
20977926
27.

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.

Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L, Neri A, Ribatti D, Rizzoli V, Martella E, Giuliani N.

Leukemia. 2010 Nov;24(11):1967-70. doi: 10.1038/leu.2010.193. Epub 2010 Sep 2. No abstract available.

PMID:
20811474
28.

Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma.

Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I.

Clin Cancer Res. 2010 Aug 15;16(16):4188-97. doi: 10.1158/1078-0432.CCR-10-0173. Epub 2010 Jun 29.

29.

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients.

Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L, Todoerti K, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi E, Palumbo A, Zuffardi O, Neri A, Rizzoli V.

Leukemia. 2010 Jul;24(7):1368-70. doi: 10.1038/leu.2010.96. Epub 2010 May 20. No abstract available.

PMID:
20485369
30.

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G, Zuffardi O, Rizzoli V, Neri A, Giuliani N.

Exp Hematol. 2010 Feb;38(2):141-53. doi: 10.1016/j.exphem.2009.11.009. Epub 2009 Dec 4.

PMID:
19963035
31.

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini C, Codeluppi K, Facchini A, Rizzoli V.

Cancer Res. 2008 Aug 15;68(16):6840-50. doi: 10.1158/0008-5472.CAN-08-0402.

32.

Mutagenic activity in wastewater concentrates from dye plants.

Fracasso ME, Leone R, Brunello F, Monastra C, Tezza F, Storti PV.

Mutat Res. 1992 Dec;298(2):91-5.

PMID:
1282216
33.

[Botulism: considerations about 8 cases occurred in the Triangulo Mineiro, Minas Gerais, Brazil].

Ferreira MS, Nishioka Sde A, de Almeida AB, Silveira PV, de Souza MC, Storti PC, Zenebon O, Gelli DS, de Souza A.

Rev Inst Med Trop Sao Paulo. 1987 May-Jun;29(3):137-41. Portuguese. No abstract available.

PMID:
3432921
34.

[The use of meprobamate in goiter with hyperthyroidism].

GUGLIELMETTI R, SIMAO R, STORTI P, STORTI C.

Hospital (Rio J). 1959 Aug;56:339-43. Portuguese. No abstract available.

PMID:
13830108

Supplemental Content

Loading ...
Support Center